Zika virus vaccine - Sanofi Pasteur

Drug Profile

Zika virus vaccine - Sanofi Pasteur

Alternative Names: Zika virus purified inactivated vaccine - Sanofi Pasteur; ZIKV vaccine - Sanofi Pasteur; ZPIV - Sanofi Pasteur

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanofi Pasteur
  • Developer National Institute of Allergy and Infectious Diseases; Sanofi Pasteur; Walter Reed Army Institute of Research
  • Class Viral vaccines; Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Zika virus infection

Most Recent Events

  • 05 Dec 2017 Adverse events data from three phase I trials in Zika virus infection released by Walter Reed Army Institute of Research
  • 08 Sep 2017 Discontinued - Phase-I for Zika virus infection (Prevention) in USA (IM)
  • 01 Sep 2017 Discontinued - Phase-I for Zika virus infection (Prevention) in Puerto Rico (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top